Board Chairman & CEO Gabriel Baertschi talks about why the private, European-based company is widening its base with new approaches and technologies for treating pain and, now, related conditions.
To understand the political peril Republicans confront in their effort to repeal and replace Obamacare, it is worth noting that many of the areas that gained the most coverage from Obamacare are the working-class districts carried by President Trump with the largest margins.
Although 99 percent of S&P 500 companies have at least one woman serving on a board, the reality is that 21 percent of these publically traded company board positions are presently filled by women.
There is a serious push to make Texas the “Third Coast” of biotech and Austin, in particular, a new hub for the industry.
Inviting FDA scientists into your manufacturing facility or laboratory for one or two days may feel unsettling, but it can be rewarding when the visits are designed to bring FDA scientists up to speed on real-world issues and new technologies.
As he walked through the former home of Ben Venue Laboratories, Niels Lynge Agerbæk didn’t see the previous failures the facility had endured.
Read all the exclusive content — including who our CMO award winners are this year — in the 2017 CMO Awards Special Edition.
The corporate VC arms of the top 10 pharmaceutical companies by sales have invested $4.7B since 2014 in 147 rounds of financing, mostly in A and B rounds and mostly in the US. Most investments are in companies with small molecules in discovery through Phase 1.
Scientists are taught to look for unexpected findings. But all too often we lock onto hypotheses that we set out to prove, and therefore end up interpreting measurements by what we are looking for. It’s not always easy to spot valuable yet unexpected results.
Here are six issues facing pharmaceutical companies to not only improve accessibility, affordability and prices but also to continue incentivizing innovation in an effort to bring highly effective, yet less expensive, drugs to market in a quick, efficient manner…
The U.S. biosimilar market is in its infancy, with only four products approved by the FDA and only two currently on the market. Passed over 30 years ago, the Hatch-Waxman Act, which allowed generic competition for branded drugs, has proven successful in decreasing drug prices while still encouraging innovation. Will the availability of biosimilars have a similar effect on the biologics market?
In January, UC San Francisco announced a research alliance with AbbVie, Amgen, and BMS supporting the collection and analysis of at least 500 tumor samples from more than 10 different forms of cancer to ultimately improve patients’ responses to cancer immunotherapy.
Being the head of any Big Pharma is bound to test an executive’s work-life balance. But when that Big Pharma is headquartered in Australia, and the company prides itself on being a “global operation,” maintaining any kind of work-life balance is a formidable task. “I’m not the poster child for how to strive for work-life balance,” admits Paul Perreault, CEO and managing director of CSL.
In 2002 Liz Lewis joined Takeda where she is currently chief counsel and head of patient advocacy at Takeda Oncology. Lewis sat down with me to share how she helped enhance Takeda Oncology’s patient advocacy organization.
The executive-level participation for Life Science Leader magazine's signature 2017 Outlook issue had an overwhelming. This year’s feature article involved 13 executive life science leaders! In part four of this series, which is a supplement to the feature magazine article, we pose the question, “Looking even further ahead, what is your vision for how the global biopharmaceutical industry might look in the year 2027?”
In case you missed it, March is the month when Life Science Leader magazine hosts its annual CMO Leadership Awards Ceremony and Reception. Held at the “W” Hotel in New York on Wednesday, March 22, 2017, this year’s event was bigger and better than in previous years. But to understand why this gathering has become not only highly embraced by industry but a signature event for biopharmaceutical contract manufacturers and those who use their services, requires understanding how the event first came about.
While watching President Trump address Congress on February, 28, 2017, I was struck by an odd sensation. Let me explain. The President was talking about the day being Rare-Disease Day, and that there was a special guest in attendance, Megan Crowley. When the television cameras panned up to show the 20-year old Notre Dame student who suffers from Pompe disease, I noticed a smiling gentleman standing next to Megan, and I thought, “I know that guy! How do I know that guy?” I considered it an odd sensation because while people often recognize someone on TV, it is rare (at least for me anyway) to feel a personal connection to the person that is smiling back at you.